Search research articles
Contact Us
Filters
Showing results (91-100 of 210) with videos related to
Page
of 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
Cancer
|
September 9, 2025
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival
Alissa J Cooper, Edoardo Garbo, Andrea Arfe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 16, 2021
Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer
Amy Cunningham-Bussel, Jiaqi Wang, Lauren C Prisco, et al.
The Lancet. Oncology
|
May 11, 2020
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A Shu, Justin F Gainor, Mark M Awad, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
JCO Precision Oncology
|
February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Cancer Cell
|
May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Scientific Reports
|
August 20, 2016
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment
Patrick H Lizotte, Robert E Jones, Lauren Keogh, et al.
Page
of 21
Search research articles
Search
Showing results (91-100 of 210) with videos related to
Sort By:
Page
of 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
Cancer
|
September 9, 2025
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival
Alissa J Cooper, Edoardo Garbo, Andrea Arfe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 16, 2021
Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer
Amy Cunningham-Bussel, Jiaqi Wang, Lauren C Prisco, et al.
The Lancet. Oncology
|
May 11, 2020
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A Shu, Justin F Gainor, Mark M Awad, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
JCO Precision Oncology
|
February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Cancer Cell
|
May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Scientific Reports
|
August 20, 2016
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment
Patrick H Lizotte, Robert E Jones, Lauren Keogh, et al.
Page
of 21